The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone)

Authors

  • Paul I. Dargan,

    1. Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK
    2. King's College London, London, UK
    Search for more papers by this author
  • Roumen Sedefov,

    1. Action on New Drugs, Epidemiology, Crime and Markets Unit, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal
    Search for more papers by this author
  • Ana Gallegos,

    1. Action on New Drugs, Epidemiology, Crime and Markets Unit, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal
    Search for more papers by this author
  • Dr David M. Wood

    Corresponding author
    1. Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK
    2. King's College London, London, UK
    • Medical Toxicology Office, 2nd Floor, Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
    Search for more papers by this author

  • Conflicts of Interest DW and PD have acted as scientific advisers to the UK Advisory Council on Misuse of Drugs (ACMD) and the European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA).

Abstract

Mephedrone (4-methylmethcathinone) is a synthetic cathinone that is used as a recreational drug. It has been available since 2007 but its availability and use increased significantly during 2009 and 2010. In this review article we will summarize the available literature on the sources, availability, and prevalence of the use of mephedrone. We will also discuss the pharmacology of mephedrone, the patterns of acute toxicity associated with its use, the reports of fatalities associated with its use, and the potential for mephedrone dependence. Copyright © 2011 John Wiley & Sons, Ltd.

Ancillary